Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16773
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jahani-Asl, Arezu | - |
dc.contributor.author | Yin, Hang | - |
dc.contributor.author | Soleimani, Vahab D | - |
dc.contributor.author | Haque, Takrima | - |
dc.contributor.author | Luchman, H Artee | - |
dc.contributor.author | Chang, Natasha C | - |
dc.contributor.author | Sincennes, Marie-Claude | - |
dc.contributor.author | Puram, Sidharth V | - |
dc.contributor.author | Scott, Andrew M | - |
dc.contributor.author | Lorimer, Ian A J | - |
dc.contributor.author | Perkins, Theodore J | - |
dc.contributor.author | Ligon, Keith L | - |
dc.contributor.author | Weiss, Samuel | - |
dc.contributor.author | Rudnicki, Michael A | - |
dc.contributor.author | Bonni, Azad | - |
dc.date | 2016-04-25 | - |
dc.date.accessioned | 2017-08-10T00:34:44Z | - |
dc.date.available | 2017-08-10T00:34:44Z | - |
dc.date.issued | 2016-06 | - |
dc.identifier.citation | Nature Neuroscience 2016; 19(6): 798-806 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16773 | - |
dc.description.abstract | EGFRvIII-STAT3 signaling is important in glioblastoma pathogenesis. Here, we identified the cytokine receptor OSMR as a direct target gene of the transcription factor STAT3 in mouse astrocytes and human brain tumor stem cells (BTSCs). We found that OSMR functioned as an essential co-receptor for EGFRvIII. OSMR formed a physical complex with EGFRvIII, and depletion of OSMR impaired EGFRvIII-STAT3 signaling. Conversely, pharmacological inhibition of EGFRvIII phosphorylation inhibited the EGFRvIII-OSMR interaction and activation of STAT3. EGFRvIII-OSMR signaling in tumors operated constitutively, whereas EGFR-OSMR signaling in nontumor cells was synergistically activated by the ligands EGF and OSM. Finally, knockdown of OSMR strongly suppressed cell proliferation and tumor growth of mouse glioblastoma cells and human BTSC xenografts in mice, and prolonged the lifespan of these mice. Our findings identify OSMR as a critical regulator of glioblastoma tumor growth that orchestrates a feed-forward signaling mechanism with EGFRvIII and STAT3 to drive tumorigenesis. | en_US |
dc.subject | Brain Neoplasms | en_US |
dc.subject | Cell Transformation, Neoplastic | en_US |
dc.subject | Cytokines | en_US |
dc.subject | Glioblastoma | en_US |
dc.subject | Signal Transduction | en_US |
dc.title | Control of glioblastoma tumorigenesis by feed-forward cytokine signaling | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Nature Neuroscience | en_US |
dc.identifier.affiliation | Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA | en_US |
dc.identifier.affiliation | Department of Neuroscience, Washington University School of Medicine, St. Louis, Missouri, USA | en_US |
dc.identifier.affiliation | Ottawa Hospital Research Institute, Ottawa, Ontario, Canada | en_US |
dc.identifier.affiliation | Department of Oncology, McGill University, Montreal, Quebec, Canada | en_US |
dc.identifier.affiliation | Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada | en_US |
dc.identifier.affiliation | Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada | en_US |
dc.identifier.affiliation | Department of Biochemistry, University of Georgia, Athens, Georgia, USA | en_US |
dc.identifier.affiliation | Molecular Biology Centre for Molecular Medicine, University of Georgia, Athens, Georgia, USA | en_US |
dc.identifier.affiliation | Department of Human Genetics, McGill University, Montreal, Quebec, Canada | en_US |
dc.identifier.affiliation | Department of Cell Biology &Anatomy, University of Calgary, Calgary, Alberta, Canada | en_US |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia | en_US |
dc.identifier.affiliation | Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada | en_US |
dc.identifier.affiliation | Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA | en_US |
dc.identifier.affiliation | Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/27110918 | en_US |
dc.identifier.doi | 10.1038/nn.4295 | en_US |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0002-6656-295X | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Scott, Andrew M | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.